4D Molecular Therapeutics, Inc. (FDMT)
After hours:
| Previous close | 23.53 |
| Open | 23.45 |
| Bid | 23.18 x 200 |
| Ask | 23.27 x 400 |
| Day's range | 22.75 - 23.85 |
| 52-week range | 9.44 - 36.25 |
| Volume | |
| Avg. volume | 1,205,009 |
| Market cap | 1.189B |
| Beta (5Y monthly) | 2.86 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.58 |
| Earnings date | 08 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 52.20 |
GuruFocus.com4D Molecular Therapeutics Inc (FDMT) Chief Legal Officer Scott Bizily Sells 8,153 Shares
On April 1, 2024, Chief Legal Officer Scott Bizily sold 8,153 shares of 4D Molecular Therapeutics Inc (NASDAQ:FDMT) according to a recent SEC Filing.
GuruFocus.com4D Molecular Therapeutics Inc's Chief Legal Officer Sells Company Shares
Scott Bizily, the Chief Legal Officer of 4D Molecular Therapeutics Inc (NASDAQ:FDMT), has sold 5,833 shares of the company on March 27, 2024, according to a recent SEC filing.
GlobeNewswire4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
Conducted initial pivotal study interactions with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA); Company has clear registration path for 4D-710 for treatment of cystic fibrosis (CF) lung disease in people with CF (pwCF) who are ineligible for or cannot tolerate approved CF modulator therapies AEROW clinical trial Phase 2 Expansion Cohort dose selection and initiation expected in Q2 2024, with pivotal trial initiation anticipated in H2 2025Initial GMP-ready suspe
